Overview

• Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations

• U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis

• CEO Keith J. Sullivan to retire in June 2026, search for successor underway

Outlook

• Company expects Q4 2025 revenue between $40 mln and $43 mln

• Neuronetics revises 2025 revenue guidance to $147 mln-$150 mln

• Company targets positive cash flow from operations in Q4 2025

Result Drivers

• GREENBROOK ACQUISITION - Revenue growth primarily driven by Greenbrook clinic acquisition

• PURCHASING PATTERNS - Decline in treatment session revenue due to changes in customer purchasing patterns

• CASH MANAGEMENT - Improved cash management with reduced cash used in operations

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Neuronetics Inc is $7.00, about 60.4% above its November 3 closing price of $2.77

Press Release: ID:nGNX3WbyNw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)